SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-056048
Filing Date
2023-10-27
Accepted
2023-10-27 17:00:10
Documents
14
Period of Report
2023-10-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20231023.htm   iXBRL 8-K 52761
2 EX-10.1 MICHAEL KING EMPLOYMENT AGREEMENT sabs-ex10_1.htm EX-10.1 177002
  Complete submission text file 0000950170-23-056048.txt   410271

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20231023_lab.xml EX-101.LAB 17250
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20231023_def.xml EX-101.DEF 13467
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20231023_pre.xml EX-101.PRE 12759
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20231023.xsd EX-101.SCH 3214
8 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20231023_htm.xml XML 6479
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 231356214
SIC: 2836 Biological Products, (No Diagnostic Substances)